Given Imaging to Present at RBC Capital Markets' Healthcare Conference
February 24 2011 - 7:00AM
Marketwired
Given Imaging (NASDAQ: GIVN) today announced that Homi Shamir,
President and CEO, will present at the RBC Capital Markets'
Healthcare Conference taking place March 2 - 3, 2011 in New York
City. Mr. Shamir's presentation is scheduled for Thursday, March
3rd at 1:30 p.m. ET.
To access a live webcast of this presentation, visit
www.givenimaging.com and click 'About Given Imaging.' The webcast
will be available in the Investor Relations section. A replay will
be available for two weeks at the above-referenced website.
About Given Imaging Ltd. Since 2001, Given
Imaging has advanced gastrointestinal visualization by developing
state-of-the art, patient-friendly tools based on its PillCam®
Platform. PillCam® capsule endoscopy uses miniature video cameras
in a capsule, wireless technology, and advanced software to provide
physicians with clear images of the small intestine via PillCam® SB
and the esophagus through PillCam® ESO. The PillCam® COLON video
capsule, which is an investigational device in the U.S., is
designed to visualize the colon. Given Imaging's other capsule
products include the Agile™ patency capsule, to verify intestinal
patency, and Bravo®, the only wireless, catheter-free, 48-hour pH
test commercially available for pH testing to assess
gastroesophageal reflux disease (GERD). In April 2010, Given
Imaging acquired Sierra Scientific Instruments, the leading
provider of specialty GI diagnostic solutions and pioneer of
high-resolution manometry for assessing gastrointestinal motility.
Sierra Scientific is now a wholly-owned subsidiary of Given
Imaging. Given Imaging's headquarters, manufacturing and R&D
facilities are located in Yoqneam, Israel, with operating
subsidiaries in the United States, Germany, France, Japan,
Australia, and Hong Kong. For more information, please visit
www.givenimaging.com.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include, but are not limited to, projections about our business and
our future revenues, expenses and profitability. Forward-looking
statements may be, but are not necessarily, identified by the use
of forward-looking terminology such as "will," "may,"
"anticipates," "estimates," "expects," "intends," "plans,"
"believes," and words and terms of similar substance.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual events,
results, performance, circumstances or achievements of the Company
to be materially different from any future events, results,
performance, circumstances or achievements expressed or implied by
such forward-looking statements. Factors that could cause actual
events, results, performance, circumstances or achievements to
differ from such forward-looking statements include, but are not
limited to, the following: (1) our ability to develop and bring to
market new products, (2) our ability to successfully complete any
necessary or required clinical studies with our products, (3) our
ability to receive regulatory clearance or approval to market our
products or changes in regulatory environment, (4) our success in
implementing our sales, marketing and manufacturing plans, (5) the
level of adoption of our products by medical practitioners, (6) the
emergence of other products that may make our products obsolete,
(7) lack of an appropriate bowel preparation materials to be used
with our PillCam COLON capsule, (8) protection and validity of
patents and other intellectual property rights, (9) the impact of
currency exchange rates, (10) the effect of competition by other
companies, (11) the outcome of significant litigation, (12) the
availability of reimbursement or other forms of funding for our
products from government and commercial payors, (13) quarterly
variations in operating results, (14) the possibility of armed
conflict or civil or military unrest in Israel, (15) the impact of
global economic conditions, (16) our ability to successfully
integrate acquired businesses, (17) changes and reforms in
applicable healthcare laws and regulations, and (18) other risks
and factors disclosed in our filings with the U.S. Securities and
Exchange Commission, including, but not limited to, risks and
factors identified under such headings as "Risk Factors,"
"Cautionary Language Regarding Forward-Looking Statements" and
"Operating Results and Financial Review and Prospects" in the
Company's Annual Report on Form 20-F for the year ended December
31, 2009. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Except for the Company's ongoing obligations to
disclose material information under the applicable securities laws,
it undertakes no obligation to release publicly any revisions to
any forward-looking statements, to report events or to report the
occurrence of unanticipated events.
For further information contact: Fern Lazar/David Carey Lazar
Partners Ltd. 1-212-867-1768 Email Contact/ Email Contact
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024